Predictive Oncology Inc. has announced that it received a letter from the Nasdaq Stock Market LLC, indicating that its common stock has closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This places the company out of compliance with Nasdaq's listing standards. The notification, dated July 8, 2025, does not immediately affect the listing of the company's stock. Predictive Oncology has until January 5, 2026, to regain compliance by achieving a bid price of at least $1.00 per share for 10 consecutive business days. If the company fails to meet this requirement, it may be eligible for additional time, provided it meets other listing standards and indicates its intention to resolve the deficiency, possibly through a reverse stock split. The company is actively monitoring the situation and exploring options to address the issue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.